Researchers sought to identify predictive markers of ustekinumab response as well as evaluate the effect of its pharmacokinetics on the clinical and endoscopic outcomes among patients with Crohn disease.
May and June 2022 FDA approvals include treatments from alopecia areata, H. pylori, Crohn disease, plaque psoriasis, and Wilson disease.
Skyrizi is first specific interleukin-23 approved to treat Crohn disease.
The incidence of Crohn disease is increasing in the US. Experts outline the risk factors, pathophysiology, and symptoms of Crohn disease as well as strategies for diagnosis and treatment of this disease in the primary care setting.
Researchers sought to identify disparities in the care and outcomes of patients with IBD of differing races and ethnicities, in order to improve health care equity.
Study authors assessed registry data to evaluate the risk of developing childhood chronic inflammatory diseases dependent on disease status of the parents.
Researchers state surgery should be considered for patients who demonstrate an inadequate response to medical therapy.
Authors say patients with hidradenitis suppurativa should be screened for inflammatory bowel disease.
Evidence insufficient for recommending changes in diet for complex carbs, refined sugars, wheat, gluten.
For both patients with ulcerative colitis and those with Crohn disease, psychiatric diagnoses were more common in those who were elderly (greater than 65 years old), women, and white, and those with psychiatric conditions more frequently had a history of alcohol abuse, tobacco and substance abuse, personality disorder, and corticosteroid use.
